Efficacy of GONB in Patients of Migraine
CompletedPhase 4NCT05679765
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The study was carried to determine the analgesic efficacy of greater occipital nerve block in patients of migraine. It was a randomised controlled which took place from april 2022 - october 2022. Fifty patients suffering from migraine were included in the study. Patients in Group G were given greater occipital nerve block (GONB) with lignocaine and dexamethasone under ultrasound guidance while those in Group S were given saline 0.9% as placebo. Pain score using Numeric Rating Scale and number of headache days was assessed at four,eight and twelve weeks after the procedure as a primary outcome. Total headache days were recorded as a secondary outcome.
Study details
- Official title
- Analgesic Efficacy of Ultrasound-guided Greater Occipital Nerve Block in Patients of Chronic Migraine
- Conditions
- Interventions
- Drug: Greater Occipital Nerve Block with dexamethasone and lidocaine
- Drug: Greater Occipital Nerve Block with 0.9% saline
- Sponsor
- Pain Medicine Department
- Start date
- 2022-04-01
- Primary completion
- 2022-08-31
- Sex
- All
- Age range
- from 18 Years to 60 Years
- Results posted
- No results posted in this snapshot
- Countries
- Pakistan
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients between 18 to 60 years * diagnosed case of migraine Exclusion Criteria: * Patients with known allergies to local anaesthetics * pregnancy * history of cranial or cervical surgery * head injury * headaches secondary to medication overuse * patients with uncontrolled systemic disease like blood pressure, diabetes mellitus * hypo or hyperthyroidism * patient who had already received GONB or botulinum toxin type A therapy within last 6 months * major psychiatric disorder * history of chronic pain syndromes
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05679765